camptothecin has been researched along with Alloxan Diabetes in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anikina, LV; Babkov, DA; Bezsonova, EN; Borisov, AV; Efremov, AM; Lozinskaya, NA; Perfilova, VN; Proskurnina, MV; Spasov, AA; Tsymlyakov, MD; Tyurenkov, IN; Zakharyascheva, OY; Zaryanova, EV | 1 |
| Deng, J; Li, K; Tang, S; Wen, P; Yang, B | 1 |
2 other study(ies) available for camptothecin and Alloxan Diabetes
| Article | Year |
|---|---|
Synthesis and biological evaluation of 3-substituted 2-oxindole derivatives as new glycogen synthase kinase 3β inhibitors.
Topics: A549 Cells; Animals; Binding Sites; Catalytic Domain; Cell Survival; Diabetes Mellitus, Experimental; Glucose Tolerance Test; Glycogen Synthase Kinase 3 beta; Humans; Inhibitory Concentration 50; Molecular Docking Simulation; Oxindoles; Protein Kinase Inhibitors; Rats; Structure-Activity Relationship | 2019 |
Tumor targetable and pH-sensitive polymer nanoparticles for simultaneously improve the Type 2 Diabetes Mellitus and malignant breast cancer.
Topics: Animals; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug Delivery Systems; Female; Humans; Hydrogen-Ion Concentration; Mice; Nanoparticles; Polymers; Tumor Microenvironment | 2022 |